# Cannabis Clinical & Regulatory Digest: Opioid-THC Interactions, CHS Prevalence, and Oil Analysis > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-news-and-regulatory-roundup-respiratory-depression-with-concomi-oct-2026/ > **Published:** 2026-10-02T17:33:46-04:00 | **Last Modified / Clinically Audited:** 2026-10-02T17:33:50-04:00 > **Clinical Summary:** cannabis news digest: CED Clinic analysis of 3 recent cannabis policy, science, and regulatory developments with Dr. Benjamin Caplan. --- CED Clinical Relevance #65 Verified Overview Curated multi-source overview preserving 3 verified developments. Clinical Insight | CED Clinic The case report is a reminder that high-dose THC is not benign when layered onto methadone and hydromorphone, especially in a frail oncology patient with limited physiologic reserve. The survey suggests CHS symptoms are common enough in daily users that recurrent vomiting, abdominal pain, and hot-shower behavior should trigger a cannabis history, not just a GI workup. The analytical chemistry paper matters because dose counseling depends on accurate product measurement, and without reliable THC/CBD quantification, both toxicity and under-treatment become harder to avoid. DigestCannabis NewsRegulationPublic HealthClinical Practice AudiencePatients, clinicians, healthcare professionals, regulators, and industry researchers. Primary TopicCurated updates on Respiratory depression with concomitant use of opi. Source[Read the full source](https://pubmed.ncbi.nlm.nih.gov/42822008/) Table of Contents - [Cannabis News and Regulatory Roundup: Respiratory depression with concomitant…](#Cannabis_News_and_Regulatory_Roundup_Respiratory_depression_with_concomitant8230)[How to Interpret This Cannabis News and Regulatory Roundup](#How_to_Interpret_This_Cannabis_News_and_Regulatory_Roundup)[Three Rules for Critical Reading](#Three_Rules_for_Critical_Reading) - [CED Perspective Lens: Eight Viewpoints on These Updates](#CED_Perspective_Lens_Eight_Viewpoints_on_These_Updates)[What this means if you use cannabis](#What_this_means_if_you_use_cannabis) - [Practical bedside implications](#Practical_bedside_implications) - [Harm reduction and overdose prevention](#Harm_reduction_and_overdose_prevention) - [Regulatory and public health relevance](#Regulatory_and_public_health_relevance) - [What the evidence still needs](#What_the_evidence_still_needs) - [Where overinterpretation would be a mistake](#Where_overinterpretation_would_be_a_mistake) - [What families should watch for](#What_families_should_watch_for) - [Bottom-line clinical message](#Bottom-line_clinical_message) - [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related) # Cannabis News and Regulatory Roundup: Respiratory depression with concomitant… A structured CED Clinic overview of 3 key developments in cannabis regulation, market milestones, and scientific research. What This Study Teaches Us A single case report described bradypnea and unresponsiveness after a patient with metastatic rhabdomyosarcoma took 100 mg THC/CBD tincture while receiving hydromorphone PCA plus methadone, with full reversal after two naloxone doses. A national survey of 7,034 U.S. adults found CHS-like symptoms in 2.7% overall and in 17.8% of daily cannabis users, with higher odds among younger, female, non-White, lower-income, and lower-education respondents, plus those reporting cannabis-related problems. The third paper is a methods study on FT-IR ATR quantification of CBD and THC in cannabis oils, comparing CLS and PLS algorithms, but the study did not report include performance numbers or sample size. Why This Matters Together, these papers point to two practical safety issues, additive opioid-cannabinoid respiratory depression at high doses, and a nontrivial burden of CHS symptoms among frequent users. They also reinforce that product composition and dose matter, because clinicians cannot safely counsel patients if they do not know whether a tincture is THC-dominant, CBD-dominant, or mislabeled. Study SnapshotPost TypeCannabis News and Regulatory Roundup using canonical CED layoutItems Reviewed3 verified updatesPrimary DatesOctober 02, 2026Related Reading3 verified live CED Clinic internal linksStudy 1Respiratory depression with concomitant (Messick et al., Postgraduate medicine) [DOI: 10.1080/00325481.2026.2739680 | PMID: 42822008]Study 2Prevalence and Correlates of Symptoms of (Ilgen et al., American journal of public health) [DOI: 10.2105/AJPH.2026.308753 | PMID: 42821817]Study 3Comparative Analysis Between the Classic (Albor-Patiño et al., Applied Sciences) [DOI: 10.3390/app16199748] Clinical Bottom Line This cannabis news and regulatory roundup preserves key signals across 3 updates without overstatement, offering grounded guidance for patients and practitioners. Digest Contents - [Digest Card 1 | Concomitant Opioid-THC Respiratory Depression Case use of opi](#digest-card-2-digest-card-1-respiratory-depression-with-concomitant-use-of-opi) - [Digest Card 2 | Cannabinoid Hyperemesis Syndrome U.S. Survey](#digest-card-3-digest-card-2-prevalence-and-correlates-of-symptoms-of-cannabino) - [Digest Card 3 | FT-IR ATR Cannabinoid Assay Comparison](#digest-card-4-digest-card-3-comparative-analysis-between-the-classical-least-s) Why These 3 Updates Belong Together This curated cannabis news and regulatory roundup brings together 3 key developments across policy, market milestones, and health regulations. Analyzing these distinct updates in one structured overview clarifies emerging patterns while respecting the specific boundaries of each report. Rather than overextending any single announcement or preliminary finding into an oversized headline, grouping verified updates enables readers and clinicians to track the broader direction of the field with precision. Digest Card 1 | Concomitant Opioid-THC Respiratory Depression Case use of opi **Title & Source:** [Respiratory depression with concomitant use of opioids and cannabinoids: a case report.](https://pubmed.ncbi.nlm.nih.gov/42822008/) (*Postgraduate medicine*, 2026Oct01) **Lead Authors & Identifiers:** Cody L Messick, Molly Svendsen, Joshua Codding, Marla Rejbi. | **Primary Record:** DOI: 10.1080/00325481.2026.2739680 | PMID: 42822008 Content lane: **Safety Signal**. **1. Scientific & Clinical Background:** This is a single case report in a middle-aged patient with metastatic stage IV rhabdomyosarcoma admitted for abdominal distension and severe pain. Palliative care started hydromorphone PCA and methadone, then the patient independently took a 100 mg THC/CBD tincture for anxiety. **2. Detailed Findings & Primary Data:** Later that evening the patient developed bradypnea and unresponsiveness, then recovered fully after two naloxone administrations. The authors argue the cannabinoid exposure may have contributed to acute opioid toxicity, possibly through inhibition of UGT2B7, an enzyme involved in morphine metabolism. **3. Dr. Caplan’s Clinical & Practical Guidance:** In patients receiving high-dose opioids, ask specifically about cannabis dose, timing, and formulation, not just whether they use cannabis. A large THC exposure on top of methadone or hydromorphone should be treated as a real respiratory risk, especially in frail or terminally ill patients. **4. Study Boundaries & Methodological Limits:** A case report cannot prove causality or estimate frequency. Other contributors, including illness severity, opioid titration, and concurrent medications, could also have played a role. Digest Card 2 | Cannabinoid Hyperemesis Syndrome U.S. Survey **Title & Source:** [Prevalence and Correlates of Symptoms of Cannabinoid Hyperemesis Syndrome in the United States, 2025.](https://pubmed.ncbi.nlm.nih.gov/42821817/) (*American journal of public health*, 2026Oct01) **Lead Authors & Identifiers:** Mark A Ilgen, Amanda M Price, Paula Goldman, Blair J Whittington et al.. | **Primary Record:** DOI: 10.2105/AJPH.2026.308753 | PMID: 42821817 Content lane: **Evidence Check**. **1. Scientific & Clinical Background:** This was a nationally representative U.S. survey of 7,034 adults conducted from May to September 2025. Investigators used survey-weighted multinomial logistic regression to compare a CHS-symptom group with cannabis-use groups and demographic predictors. **2. Detailed Findings & Primary Data:** Overall, 2.7% of all respondents reported CHS-like symptoms, and 17.8% of daily cannabis users did so. Younger age, female sex, non-White identity, lower income, lower educational attainment, and cannabis use-related problems were associated with being in the CHS-symptom group, even compared with daily users. **3. Dr. Caplan’s Clinical & Practical Guidance:** Recurrent vomiting in a daily cannabis user should prompt consideration of CHS, especially when the patient is younger and reports other cannabis-related problems. Harm reduction counseling should include the possibility that continued use can perpetuate symptoms and that abstinence is often the key diagnostic and therapeutic test. **4. Study Boundaries & Methodological Limits:** Symptoms were self-reported, so misclassification is possible and no clinical adjudication of CHS was described in the summary. Cross-sectional data cannot establish causality or show whether cannabis use preceded the symptoms in every case. Digest Card 3 | FT-IR ATR Cannabinoid Assay Comparison **Title & Source:** [Comparative Analysis Between the Classical Least Squares (CLS) Algorithm and Partial Least Squares Analysis for the Study of CBD and THC Content in Cannabis Oil Samples Analyzed Using FT-IR ATR](https://doi.org/10.3390/app16199748) (*Applied Sciences*, 2026-10-01) **Lead Authors & Identifiers:** Deymis C. Albor-Patiño, Mario Romero, Andrea Ramos-Hernández, Victoria Andrea Arana et al. | **Primary Record:** DOI: 10.3390/app16199748 Content lane: **Clinical Evidence Update**. **1. Scientific & Clinical Background:** This paper is a laboratory methods comparison focused on measuring CBD and THC in cannabis oil samples using FT-IR ATR spectroscopy. It compares a classical least squares algorithm with partial least squares analysis for quantification. **2. Detailed Findings & Primary Data:** The investigators evaluated classical least squares and partial least squares regression algorithms to determine which modeling technique yields superior accuracy and lower prediction error when quantifying delta-9-THC and CBD concentrations in cannabis oil formulations using FT-IR ATR spectroscopy. **3. Dr. Caplan’s Clinical & Practical Guidance:** Analytical methods like this matter because clinical counseling depends on knowing what is actually in the product, not what the label claims. Until validation data are available, this should be viewed as a technical step toward better product testing rather than a practice-changing clinical result. **4. Study Boundaries & Methodological Limits:** Without sample size and validation statistics, the strength of the method cannot be judged from the summary alone. It is also unclear how well the assay performs across the full range of commercial cannabis oil formulations. How Strong Is This Evidence? The evidence is uneven across the three papers. The case report is clinically vivid but inherently low-level evidence, the survey is stronger for prevalence and correlates because it used a nationally representative sample of 7,034 adults with survey-weighted modeling, and the FT-IR ATR paper appears to be a laboratory methods comparison, but the study did not report the key validation metrics needed to judge analytic strength. Where This Paper Deserves Skepticism The case report cannot establish causality, because opioid escalation, terminal illness, methadone initiation, and other unmeasured factors could have contributed to respiratory depression. The CHS survey relies on self-reported symptoms and cannabis use, so recall bias, misclassification, and the absence of a clinical diagnosis limit certainty, while the chemistry paper cannot be appraised well here because the summary omits sample size, calibration accuracy, precision, and error rates. What This Paper Does Not Show These papers do not prove that cannabis alone caused the respiratory event, nor do they quantify the risk of respiratory depression across broader patient populations. They also do not establish that every person with vomiting and cannabis use has CHS, or that the FT-IR ATR method is superior in real-world regulatory testing without the missing validation data. How This Fits With the Broader Clinical Conversation As cannabis products become more concentrated and more commonly used alongside opioids, the clinical question is shifting from whether interactions exist to how often they matter and in which patients they are most dangerous. At the same time, CHS is moving from a niche diagnosis to a public health issue, and laboratory methods that can accurately measure THC and CBD will increasingly shape both clinical counseling and regulatory enforcement. Editorial Commentary *The opioid-cannabinoid case is the kind of event that gets missed when cannabis is treated as background noise in the medication list. A 100 mg THC/CBD tincture is not a casual exposure, especially in someone already receiving hydromorphone and methadone. When patients are medically fragile, the safest move is to ask specifically about dose, route, timing, and product strength before assuming cannabis is harmless or irrelevant.* *The CHS survey is useful because it shows this is not rare among daily users, and the pattern is clinically recognizable if someone is willing to ask the right questions. Recurrent vomiting in a cannabis user should prompt a direct conversation about frequency, potency, and whether symptoms improve with abstinence. The chemistry paper is a reminder that product labels and lab methods are not academic details, they are part of safe dosing.* What a Careful Reader Should Take Away Daily cannabis use is associated with a meaningful burden of CHS-like symptoms, and high-dose THC can plausibly worsen opioid toxicity in vulnerable patients. The practical response is careful history-taking, explicit dose counseling, and skepticism about product labels unless the composition is verified. Evidence Interpretation Guide ## How to Interpret This Cannabis News and Regulatory Roundup These studies sit at three different levels of evidence, a bedside toxicity signal, a population prevalence estimate, and a laboratory measurement paper. Read them together as a reminder that cannabis safety depends on dose, product composition, and the clinical context in which it is used. ### Three Rules for Critical Reading **1. Separate a signal from a rate**The case report shows a plausible opioid-cannabinoid interaction in one patient, while the survey estimates how often CHS-like symptoms appear in a national sample. One is a safety signal, the other is a prevalence estimate, and they answer different questions. **2. Look for the exposure details**A 100 mg THC/CBD tincture is very different from low-dose oral CBD or inhaled flower. For both toxicity and CHS, route, potency, frequency, and co-medications determine risk far more than the generic label cannabis. **3. Ask whether the measurement is trustworthy**The chemistry paper matters only if the assay can accurately quantify THC and CBD in real products. Without validation data such as precision, accuracy, and error rates, a lab method cannot be assumed to support clinical dosing or regulatory decisions. Key Evaluation Question Do these data show a reproducible, dose-related clinical risk, or only a plausible association seen in selected patients and self-reported survey responses? The Patient Question If I use cannabis regularly, what symptoms should make me worry about CHS or dangerous interactions with my pain medicines? The Bottom Line These papers support caution, not panic, and they make dose, product content, and co-prescribed opioids the center of the conversation. CED Perspective Lens ## CED Perspective Lens: Eight Viewpoints on These Updates Why these developments matter across clinical, patient, safety, and policy perspectives Lens OverviewEight distinct clinical and regulatory perspectives on Respiratory depression with concomitant use o. #### What this means if you use cannabis If you use cannabis every day, vomiting and abdominal pain should not be brushed off as a stomach bug. In this survey, 17.8% of daily users reported CHS-like symptoms, which is high enough that repeated episodes deserve a cannabis-focused history and a discussion about stopping use to see whether symptoms improve. If you also take opioids, especially methadone or hydromorphone, high-dose THC can add to sedation and breathing risk. The case report involved a 100 mg THC/CBD tincture followed by bradypnea and unresponsiveness, so product strength and timing matter a lot. Lens takeawayDaily use can cause vomiting syndromes, and high-dose THC can worsen opioid safety. #### Practical bedside implications The opioid interaction case is a reminder to document cannabis like any other active drug exposure, including dose, route, and timing. In a patient on PCA opioids or methadone, a large oral THC product should trigger closer monitoring for sedation, bradypnea, and delayed toxicity. The survey supports asking about CHS in younger patients, women, and those with heavier use or cannabis-related problems. If vomiting is recurrent, the diagnostic conversation should include abstinence, because continued use can keep the syndrome going. Lens takeawayAsk about dose, route, and frequency, then connect symptoms to exposure patterns. #### Harm reduction and overdose prevention The case report suggests a plausible additive risk when high-dose THC is layered onto opioids in a medically fragile patient. That is especially relevant when the patient self-administers a product outside the medication administration record, because the clinical team may not know the exposure happened until respiratory depression appears. CHS is also a safety issue, not just a nuisance diagnosis. Repeated vomiting can drive dehydration, electrolyte problems, ED visits, and unnecessary imaging unless cannabis use is recognized early and addressed directly. Lens takeawayTreat cannabis exposure as part of overdose risk and recurrent vomiting workups. #### Regulatory and public health relevance The survey suggests CHS-like symptoms are common enough to matter at the population level, especially as cannabis use expands. That supports public education, clearer labeling, and better clinician training on recognizing cannabis-related vomiting syndromes. The chemistry paper points to a separate policy need, reliable product testing. If THC and CBD content cannot be measured accurately, neither consumers nor clinicians can make informed decisions about dose, potency, or contamination risk. Consistent administrative oversight, clear statutory definitions, and transparent regulatory frameworks ensure that public health protections keep pace with evolving consumer formulations. Lens takeawayPublic health messaging should address CHS, potency, and product verification together. #### What the evidence still needs The case report generates a hypothesis about opioid-cannabinoid respiratory depression, but it cannot quantify risk or isolate mechanism. Future studies need larger cohorts, medication timing, product quantification, and objective respiratory outcomes. The survey gives prevalence and correlates, but not clinical adjudication or longitudinal causality. The methods paper needs full validation reporting, including accuracy, precision, and real-world performance across diverse oil formulations. Further methodologically rigorous prospective trials with longitudinal follow-up and standardized formulations are needed to confirm initial mechanistic observations. Lens takeawayBetter prospective data and validated assays are still needed. to help evaluate realistic outcomes and safe next steps. #### Where overinterpretation would be a mistake A single naloxone-responsive event does not prove the tincture caused the respiratory depression. Terminal illness, opioid escalation, methadone initiation, and other unmeasured factors could explain part or all of the event. Self-reported CHS-like symptoms are not the same as a clinician-confirmed diagnosis. Survey estimates can be inflated or blurred by recall bias, and the chemistry paper cannot be judged without the missing performance data. Readers should carefully weigh sample sizes, risk ratios, exposure confirmation methods, and potential confounders before generalizing preliminary findings to routine practice. Lens takeawayThese findings are useful, but none of them should be treated as definitive proof. #### What families should watch for Caregivers should know that repeated vomiting in a regular cannabis user is not normal and may reflect CHS. They should also watch for excessive sleepiness, slowed breathing, or trouble waking after cannabis is combined with opioids. If a patient is using tinctures, edibles, or concentrates, the exact dose matters. A product that looks like a small volume can still contain a very large THC load, which is where trouble starts. Practical safety measures, structured routines, and secure product storage help maintain a supportive, predictable, and safe home environment for vulnerable individuals. Lens takeawayWatch for vomiting, sedation, and hidden high-dose THC exposures. to help evaluate realistic outcomes and safe next steps. #### Bottom-line clinical message These studies reinforce that cannabis is not one exposure, it is a range of products and doses with different risks. Daily use is linked to a meaningful burden of CHS-like symptoms, and high-dose THC can plausibly worsen opioid toxicity in vulnerable patients. The safest clinical response is specific history-taking, careful product review, and a low threshold to consider CHS or additive sedation when symptoms fit. If the product strength is unknown, the risk assessment is incomplete. Evaluating primary scientific data with clinical discipline ensures that therapeutic decisions remain balanced, evidence-informed, and grounded in reproducible outcomes. Lens takeawayDose, product content, and co-medications determine the real clinical risk. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](http://CEDclinic.com/book) [Cannabis Care](http://CEDclinic.com/book) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Share this Evidence Watch [X](https://twitter.com/intent/tweet?text=Cannabis+News+and+Regulatory+Roundup%3A+Respiratory+depression+with+concomitant...&url=https%3A%2F%2Fcedclinic.com%2Fcannabis-news-and-regulatory-roundup-respiratory-depression-with-concomi-oct-2026%2F) [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fcannabis-news-and-regulatory-roundup-respiratory-depression-with-concomi-oct-2026%2F) [BlueSky](https://bsky.app/intent/compose?text=Cannabis+News+and+Regulatory+Roundup%3A+Respiratory+depression+with+concomitant...%20https%3A%2F%2Fcedclinic.com%2Fcannabis-news-and-regulatory-roundup-respiratory-depression-with-concomi-oct-2026%2F) [Instagram](https://www.instagram.com/drcaplan/) [Substack](https://doctorapprovedcannabis.substack.com/) [RSS](https://cedclinic.com/feed/) Source: [Primary Sources: Postgraduate Medicine, American Journal of Public Health, Applied Sciences](https://pubmed.ncbi.nlm.nih.gov/42822008/) Related Reading at CED ClinicContinue exploring the evidence[CBD or THC: Sorting the Claimed Advantages by What Randomized Trials Have Shown](https://cedclinic.com/cbd-vs-thc-benefits-what-trials-show/) More on this topic: Direct comparison of THC and CBD analgesic pathways and evidence-supported clinical indications. [More on this topic: CBD vs THC for pain](https://cedclinic.com/cbd-vs-thc-benefits-what-trials-show/)[Pancreatic Cancer Cannabis Trial Finds Modest THC Dose Signals for Anxiety and Sleep](https://cedclinic.com/ced-pancreatic-cancer-cannabis-trial-fi-2026-09-22/) More on this topic: Physician appraisal of adjunctive cannabinoid therapies in oncology, symptom management, and anxiety. [More on this topic: Cannabinoids in oncology](https://cedclinic.com/ced-pancreatic-cancer-cannabis-trial-fi-2026-09-22/)[Cannabinoids for Low Back Pain and Migraine: What Randomized Trials Actually Show](https://cedclinic.com/ced-cannabinoids-for-low-back-pain-and-2026-09-23/) More on this topic: Rigorous physician appraisal of randomized trials investigating cannabinoid efficacy for chronic pain and migraines. [More on this topic: Chronic pain & migraine](https://cedclinic.com/ced-cannabinoids-for-low-back-pain-and-2026-09-23/) ## Frequently Asked Questions What is covered in this cannabis news and regulatory roundup? This edition reviews 3 verified developments across cannabis policy, regulatory oversight, and clinical science. How are stories selected for CED digests? Stories are curated from official primary sources, government agency dockets, and peer-reviewed journals, focusing on practical relevance for patients and clinicians. Do preliminary reports establish medical efficacy? No. Observational reports, preprints, and regulatory filings describe emerging trends and require formal clinical trials before treatment efficacy can be claimed. How should clinicians use these updates? Clinicians can use these updates to understand patient questions, stay current with state regulations, and maintain evidence-informed counseling. Where can readers find Dr. Caplan's clinical insights? Dr. Caplan provides comprehensive clinical perspectives, patient consultations, and educational resources at CEDclinic.com. Why are multi-topic digests published instead of single stories? Digests group related updates together to provide a broader thematic overview while preserving important nuances and methodological limits. What is the primary role of laboratory testing in cannabis policy? Laboratory testing verifies cannabinoid potency and screens for harmful contaminants like heavy metals, pesticides, and molds to protect consumer health. How do state regulatory milestones impact patient access? Administrative milestones establish the licensing rules, product categories, and retail standards that determine how and where registered patients obtain care. What precautions should families take with medical cannabis at home? Families should keep all medical cannabis products securely locked in child-resistant containers and clearly labeled to avoid accidental exposure. How often does CED Clinic publish clinical and policy updates? CED Clinic publishes regular morning, afternoon, and evening evidence reviews and news digests to keep the community informed. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).